Xiantuo Wu
Hematology & Oncology · Las Vegas, NVNPI 1639397631
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,928 of the $35,030 with a category attached, or 62.6%. 26 manufacturers reported payments, led by Incyte Corporation at 32.9% of the total.
Across 95 payments — averaging $368.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$12K
- AstraZeneca$8K
- Karyopharm Therapeutics Inc.$4K
- Avyxa Pharma, LLC$4K
- ADC Therapeutics America, Inc.$2K
- Pfizer$2K
- plus $4K from 20 others
What the payments were for
- Consulting fees$21,92863%
- Speaking & faculty fees$3,75011%
- Travel & lodging$5,32315%
- Food & beverage$3,0339%
- Education$9963%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 13 | $11,519 |
| AstraZeneca | 12 | $7,581 |
| Karyopharm Therapeutics Inc. | 6 | $4,213 |
| Avyxa Pharma, LLC | 7 | $4,205 |
| ADC Therapeutics America, Inc. | 1 | $2,000 |
| Pfizer | 1 | $1,750 |
| Beigene USA, Inc. | 1 | $675 |
| AbbVie(2 entities) | 10 | $573 |
| Johnson & Johnson(2 entities) | 6 | $470 |
| Seagen Inc. | 6 | $444 |
| Cardinal Health 110 LLC | 1 | $275 |
| GSK | 11 | $205 |
| Sobi, Inc | 7 | $188 |
| Verastem, Inc. | 1 | $124 |
| Lilly USA, LLC | 1 | $123 |
| Stemline Therapeutics Inc. | 1 | $122 |
| AVEO Pharmaceuticals, Inc. | 1 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Eisai Inc. | 1 | $99 |
| Gilead | 1 | $99 |
| Coherus Oncology, Inc. | 1 | $60 |
| Daiichi Sankyo Inc. | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Exelixis Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $19 |
| Biocomposites Inc | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,030 in reported general payments places this provider in the 75th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 83 | $1,173,430 |
| JakafiRuxolitinib Phosphate | 58 | $819,636 |
| RevlimidLenalidomide | 43 | $616,207 |
| TagrissoOsimertinib Mesylate | 29 | $471,835 |
| InrebicFedratinib Dihydrochloride | 17 | $384,902 |
| CalquenceAcalabrutinib Maleate | 23 | $337,257 |
| LynparzaOlaparib | 18 | $295,309 |
| TasignaNilotinib Hcl | 14 | $274,970 |
| IclusigPonatinib Hcl | 11 | $240,873 |
| XtandiEnzalutamide | 16 | $230,478 |
| KisqaliRibociclib Succinate | 12 | $200,641 |
| VenclextaVenetoclax | 23 | $183,653 |
| ImbruvicaIbrutinib | 11 | $180,572 |
| MekinistTrametinib Dimethyl Sulfoxide | 11 | $179,196 |
| BrukinsaZanubrutinib | 12 | $169,944 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $470 | $1,173,43083 claims |
| AstraZenecaTagrisso, Calquence, Lynparza | $7,581 | $1,104,40270 claims |
| Bristol Myers SquibbRevlimid, Inrebic | $19 | $1,001,10960 claims |
| Incyte CorporationJakafi | $11,519 | $819,63658 claims |
| AbbVieVenclexta | $573 | $183,65323 claims |
| Beigene USA, Inc.Brukinsa | $675 | $169,94412 claims |
| PfizerEliquis | $1,750 | $43,19850 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Las Vegas
- Nicholas VogelzangLas Vegas$397K
- Wolfram SamlowskiLas Vegas$235K
- Oscar GoodmanLas Vegas$211K
- Aaron GoodmanLas Vegas$134K
- Anuradha ThummalaLas Vegas$128K
- Ann WiermanLas Vegas$81K
- Heather AllenLas Vegas$78K
- Holavanahalli Keshava-PrasadLas Vegas$67K
- Edgardo FaylonaLas Vegas$53K
- Khawaja JahangirLas Vegas$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.